Alessandro Doria, Ph.D., M.D.
This page shows the publications co-authored by Alessandro Doria and Mario Luca Morieri.
Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes. J Am Coll Cardiol. 2020 06 16; 75(23):2995-2996.
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes. 2020 04; 69(4):771-783.
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. Diabetes Care. 2018 Nov; 41(11):2404-2413.
Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. Diabetes Care. 2018 02; 41(2):348-355.
Variants in ANGPTL4 and the Risk of Coronary Artery Disease. N Engl J Med. 2016 12 08; 375(23):2304-2305.
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care. 2016 Nov; 39(11):1915-1924.
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clin Pharmacol Ther. 2018 04; 103(4):712-721.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.